摘要
目的比较阿立哌唑与利培酮治疗首发精神分裂症的疗效及不良反应。方法选择我院诊断为精神分裂症患者73例,随机进入阿立哌唑组或利培酮组接受治疗,分别在治疗0、2、4、8周,采用阳性与阴性症状量表(PANSS)和不良反应量表(TESS)评定其疗效和不良反应。结果阿立哌唑与利培酮疗效相当,阿立哌唑能迅速控制精神症状,产生不良反应小。结论阿立哌唑对首发精神分裂症治疗安全有效。
Objective To analyze aripiprazole will profit and risperidone in the treatment of first episode schizophrenia effects and adverse reactions. Methods Choose 73 cases in our hospital diagnosed with schizophrenia patients, randomly divided into the aripiprazole group and the risperidone group, using positive and negative symptoms scale（PANSS）and adverse event scale （TESS）to assess the efficacy and adverse reactions after treatment of 0,2,4,8 weeks. Results Aripiprazolein has equivalent efficacy to risperidone and controls mental symptom faster and has less adverse reactions. Conclusion Aripi prazole is safe and effective in the treatment of first episode schizophrenia.
出处
《中国医药指南》
2014年第21期20-21,共2页
Guide of China Medicine
